Basic Information
PRIORIX VACCINE
INJECTION, POWDER, FOR SOLUTION
Regulatory Information
SIN10822P
March 22, 1999
Prescription Only
Therapeutic
SUBCUTANEOUS, INTRAMUSCULAR
August 10, 2023
June 3, 2025
XJ07BD52
Company Information
GLAXOSMITHKLINE PTE LTD
GLAXOSMITHKLINE PTE LTD
Active Ingredients
Strength: min 1000 TCID50
Strength: min 1000 TCID50
Strength: min 5000 TCID50
Detailed Information
Contraindications
**Contraindications** **Priorix** is contraindicated in subjects with known systemic hypersensitivity to neomycin or to any other component of the vaccine (for egg allergy, see “ _Warnings and Precautions_” – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). A history of contact dermatitis to neomycin is not a contraindication. **Priorix** is contraindicated in subjects having shown signs of hypersensitivity after previous administration of measles, mumps and/or rubella vaccines. **Priorix** is contraindicated in subjects with severe humoral or cellular (primary or acquired) immunodeficiency e.g. symptomatic HIV infection (see also “ _Warnings and Precautions_” – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). **Priorix** is contraindicated in pregnant women. Pregnancy should be avoided for one month after vaccination (see “ _Pregnancy and Lactation_” – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**Indications** **Priorix** is indicated for the active immunisation against measles, mumps and rubella.